Alpha Cognition Inc - Asset Resilience Ratio
Alpha Cognition Inc (ACOG) has an Asset Resilience Ratio of 40.47% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how Alpha Cognition Inc's Asset Resilience Ratio has changed over time. See financial agility of Alpha Cognition Inc to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Alpha Cognition Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Alpha Cognition Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.41 Million | 40.47% |
| Total Liquid Assets | $1.41 Million | 40.47% |
Asset Resilience Insights
- Very High Liquidity: Alpha Cognition Inc maintains exceptional liquid asset reserves at 40.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alpha Cognition Inc Industry Peers by Asset Resilience Ratio
Compare Alpha Cognition Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Alpha Cognition Inc (None–None)
The table below shows the annual Asset Resilience Ratio data for Alpha Cognition Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatm… Read more